For instance, several preclinical studies have indicated that CDK4/6i can boost tumor cell immunogenicity, leading to the exploration of CDK4/6i and Immune checkpoint inhibitor (ICI) combinations [11, 12]. The gene discussed is CDK4; the disease is neoplasm.